Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations.

Eur J Health Econ · 2021 · PMC8166732 · PMID 33677736

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

2 a, suggesting sevelamer was more cost-effective than CBPBs, although this failed to reach statistical significance.

also in 6,035 other papers

failed to reach significanceno p-value reported

Sevelamer was more cost-effective than CBPBs in pre-dialysis, but not in dialysis patients, with and without accounting for dialysis costs (i.e., pooled INBs were $19,145.8 (− 27,797.5 to 66,089.2), − $1.986.5 (− 67.671.7 to 63,698.8), and − $2760.8 (− 49,203.4 to 43,681.8), respectively, but again all estimates failed to reach significance.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.